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the proximal edge of the SG (C-TAG) slid into the orifice of the LCA resulting in
occlusion. The subsequently performed LCA-RCA-bypass resolved the perfusion
without cerebral deficit. In two another pts distal migration of the SG (C-TAG) was
followed by secondary conversion with open thoracic tube graft repair (n=1), or arch
debranching and subsequently performed TEVAR(n=1). Proximal stent graft apposition
was excellent in 29/42 cases, good in 12/42 cases, and bad in 1 case. No type I endoleak
was detectable. In comparison to matched cases treated with former generation of SG
the apposition scoring was significantly better.
Conclusion: The newly available thoracic SG both improves proximal apposition of
the device at the inner curve of the aortic arch. More data and longer follow-up are
required to confirm the applicability of this technique.
TCT-562
Retrograde transpedal access for below-the-knee chronic total occlusions after
failed anterograde recanalisation
Zoltán Ruzsa1, 2, Balázs Nemes1, Károly Tóth2, Ferenc Kuti2, István Koncz2, Zoltán
Bánsághy2, Kálmán Hüttl Prof1, Béla Merkely Prof1
1Cardiology Center, Semmelweis University, Budapest, Hungary; 2Bács-Kiskun
Hospital, Kecskemét, Hungary
Background: The purpose of the study was to evaluate the acute success and clinical
impact of retrograde transpedal access for retrograde below-the-knee artery (BTK)
chronic total occlusions (CTO) after failed attempts to re-enter the true lumen in the
anterograde femoral approach.
Methods: The clinical and angiographic data of 28 consecutive patients with CLI
treated by retrograde transpedal recanalisation between 2010 and 2011.02 were
evaluated in a pilot study. Patients received daily aspirin, clopidogrel during the
procedure. We examinated the one-month major adverse events (MAEs). Clinical
success was defined as relief of resting pain, healing of ulceration or avoidance of
amputation. After re-entry to the true lumen failed or the guidewire passage was
unsuccesfull during anterograde approach, the anterior tibial or posterior tibial artery
was punctured with a transradial 20 G needle under fluoroscopic guidance and coronary
guidewire was advanced in the artery.
Results: 26 (92.8%) of 28 procedures were finished successfully with a good
angiographic result and flow. The failure rate was 7.2% (1 unsuccessfull puncture and
1 failed reentry). Balloon angioplasty was performed in all successfull interventions
and provisional stenting was done in 7 patients (27%). The procedure was finalised
with anterograde rotational atherectomy in one case (3.5%) due to inability to pass the
balloon. No major access site complications occured; however three transient spasm
was found in the investigated population (11%). Technical and clinical success was
observed in 26 (92.8%) and in 25 patients (89.2%). The MAE in the investigated
population was 3.57% (2 major amputations).
Conclusion: Failed antegrade attempts to recanalise CTO-s of BTK vessels can be
salvaged using a retrograde transpedal access, with a low complication rate. This
technique could be valuable for patients with critical limb ischemia due to popliteal
and infrapopliteal occlusions once larger studies with follow-up confirm safety,
efficacy, and clinical benefit.
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Five-Year Trial of TASC II Type C/D Lesions Undergoing Subintimal
Angioplasty or Bypass Surgery Based on Plaque Echolucency
Niamh Hynes2, 1, Sherif Sultan1, 2
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Background: 5-year study comparing the effectiveness of subintimal angioplasty
(SIA) to bypass grafting (BG) for treatment of TASC II type C/D lesions in patients
with critical limb ischemia (CLI).
Methods: Of 1076 patients referred with PVD from 2002 to 2007, 206 SIAs in 190
patients and 128 bypass grafts in 119 patients were enrolled in the study. All patients
had rest pain and/or tissue loss. Primary endpoints were survival free from amputation
and sustained clinical improvement. Secondary endpoints were major adverse events
(MAE), the binary restenosis rate, freedom from TLR, and a special quality-adjusted
life year (QALY) endpoint (Q-TWiST) that incorporated both length and quality of
life to evaluate treatments
Results: At 5 years, clinical improvement was sustained in 82.8% of the SIA group
versus 68.2% of the BG patients (p50.106). Five-year all-cause survival was similar
for SIA (78.6%) and BG (80.1%; p=0.734), as was amputation-free survival (SIA
72.9% versus BG 71.2%;p=0.976). Hyperfibrinogenemia (p=0.009) and C-reactive
protein (p=0.019) had negative effects on survival without amputation. Five-year
freedom from binary restenosis rates were 72.8% for SIA versus 65.3% for BG
(p=0.700). While the 5-year freedom from TLR rates (SIA 85.9% versus BS 72.1%,
p=0.262) were not statistically significant, the risk of MAE (p<0.002) and length of
hospital stay (p<0.0001) were significantly reduced. Q-TWiST significantly improved
(p<0.001) and cost-per-QALY was reduced with SIA. The 5-year risk of re-intervention
(p>0.05) and mean number of procedures (p=0.078) were similar.
Conclusion: Five-year freedom from MAE was enhanced by 20% in the SIA group,
with substantial cost reduction and better Q-TWiST. SIA is a minimally invasive
technique that expands amputation-free and symptom-free survival. SIA is a paradigm
shift in the management of CLI.
TCT-564
Vertebral Angioplasty Stenting. Are Protection Devices Useful?
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Background: It is now clear that atheroemboli are the rule in any intervention in
atherosclerotic disease and seems the root cause of many procedural
complications.Embolic Protection Devices(EPD) are largely used to reduce the nb of
cerebral emboli during carotid angioplasty stenting(CAS).Recent studies have shown
a high incidence of emboli during Vertebral Angioplasty Stenting(VAS) & a
comparable frequency & amount of captured emboli during VAS and carotid
angioplasty stenting. Neurological complications after VAS are not frequent but could
be devastating.So the use of EPD for VAS may be advisable & should reduce the
neurological complications during VAS
Methods: We retrospectively determined rates of technical success & 1 month stroke
and death associated with stent placement by using EPD (Filterwire)and a new filter
Fibernet (Lumen Biomedical) in pts with symptomatic ostial VA stenoses. Technical
success was defined as successful EPD deployment and stent placement,successful
EPD retrieval & a residual stenosis<30%. 30 day outcomes included any stroke &
death. The new EPD (Fibernet) allows capture of debris of 40μ without compromising
the flow. Its retrieval catheter is an aspiration catheter allowing meticulous cleaning
of the vessel and of the dilated area
Results: In a series of 102 VAS 10 pts treated with EPD. Mean age 69 y.(63-80).˛:8,
left6. Mean% stenosis 80,9±6,8. Mean arterial Ø:4,8±0,5mm. Femoral approach used
in all cases. Filterwire:8 pts,Fibernet:2. Technical success was achieved for the 10 pts.
Postprocedure residual stenoses:4±3%. Visible debris were removed in 70%of cases
(Filterwire:5 and Fibernet:2).Filter deployment time:10mm (7-13mm).No stroke or
death observed at 1 month. With Fibernet mean debris area:184 mm2.(aspirated
debris:114mm2,debris in the filter70 mm2) Debris analysis will be reported. These
results are comparable to the results obtained in CAS
Conclusion: The present study demonstrates the feasibility and safety of VAS using
EPD. Further studies are required to determine the exact role of EPD and their
indications in VAS. It seems that the results obtained in VAS are comparable to those
obtained after CAS.
TCT-565
The Role of Pull-Back Pressure Gradient in Percutaneous Transluminal
Angioplasty for Central Vein stenosis in Dialysis Patients
Yu Sheng Lin1, Cheng-Hsu Yang2, Chi-Yung Fang2, Chien-Jen Chen2, Chiung-Jen
Wu2
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Background: The severity of residual stenosis (RS) in central vein stenosis(CVS)
sometimes hard to be accurately measured by angiographic image. Because of
intracoronary pressure is good alternative parameter in coronary intervention, the role
of pull-back pressure measurement in percutaneous transluminal angioplasty for CVS
was evaluated.
Methods: This study retrospectively reviewed consecutive 94 dialysis patients asked
for management of CVS which were divided into two groups by aniographic image or
post-intervention pressure gradient (PG), and followed up long term clinical outcomes.
12-month patency rate between groups were compared and analyzed.
Results: The 94 patients consisted of 47 males and 47 females. There were divided
into two groups which included 63 cases in successful group (RS<30%) and 31 cases
in acceptable group (50%>RS>30% ) by aniographic criteria, or which included 51
cases in PG<5 mmHg(PG1 group) and 43 cases in PG>5mmHg(PG2 group) by
measured pullback PG. the baseline characteristics and parameters during intervention
between groups were almost no statistical difference. 12-month patency rate in
successful group vs. acceptable group were 54% vs. 39%( P= 0.167), while in PG1
group and PG2 group were 60% vs 37% ( P= 0.048). Further, subgroup analysis
between PG1 group vs. group accordance to the criteria of accepted group plus PG2
group were 60% vs 29%(P=0.058).
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Conclusion: Post-intervention pull-back PG is a good alternative parameter for
angioplasty in CVS in dialysis patients, particular in cases of which RS was not
accordance to the criteria of successful intervention or not accurately defined.
TCT-566
Nitinol stent implantation for TASC C and D lesions in the superficial femoral
artery (STELLA trial)
Yann Gouëffic1, Jean-Michel Davaine1, Delasalle Béatrice2, Laure Azéma1, Alain
Costargent1, David Pintoux1, Philippe Chaillou1, Philippe Patra1
1Department of vascular surgery, Institut du thorax, University Hospital of Nantes,
Nantes, France; 2Institut du thorax, University Hospital of Nantes, Nantes, France
Background: Currently, no data support nitinol stent implantation as an alternative
treatment for long lesions in the superficial femoral artery (SFA). STELLA was a
prospective trial designed to evaluate the safety and the efficacy of primary stenting
for TASC C and D lesions in the SFA.
Methods: From November 2008 to October 2009, patients with TASC C and D de
novo SFA lesions were treated with the same endovascular technique that included
primary nitinol self-expanding stent (LifeStent, Bard Peripheral Vascular, USA)
implantation. The patients were included in a prospective single-center registry, and
were followed at 1, 3, 6, 9, 12 and 18 months. The primary endpoint was the primary
sustained clinical improvement at 12 months.
Results: Fifty-eight patients (62 limbs) were enrolled in the study (42 men; mean age:
71 years). Patients suffered from claudication (40.3%) and from critical limb ischemia
(59.7%). Lesions were TASC C (62.9%) and TASC D (37.1%). The mean length of
the treated segments was 236 mm ± 99 mm. The mean number of stents per treated
limb was 2.2. The mean hospital length of stay was 3 days (range 0 to 16 days). The
mean follow-up was 17 months, with one patient lost to follow-up. At 1 year post-
procedure, the primary endpoint of primary clinical improvement was 68.6% while
secondary sustained clinical improvement was 82.6%. Freedom from target lesion and
target vessel revascularisation were 81.1% and 96.3%. Primary and secondary
patencies were 66% and 80.9%. The ankle brachial pressure index increased from 0.58
to 0.94 (p= 0.001) and the incidence of in-stent restenosis was 19.3%.
Conclusion: Primary stenting for TASC C and D lesions in the SFA appears to be a
safe technique with acceptable clinical outcomes at 1 year. These data support the use
of endovascular repair for TASC C and D lesions in the SFA.
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The Multilayer Stent for the Treatment of Popliteal Aneurysm
Michel Henry1, 2, Amira Benjelloun3, Antonios Polydorou4, Isabelle Henry5
1CABINET DE CARDIOLOGIE, Nancy, France; 2Global Research Institute,
Hyderabad, India; 3Clinique Coeur et Vaisseaux, Rabat Sale, Morocco;
4Pantaleimon General Hospital, Athens, Greece; 5Polyclinique Bois Bernard, Bois
Bernard, France
Background: Popliteal Artery Aneurysms (PA) are traditionally treated surgically.
Endovascular procedures with implantation of stent grafts or covered stents have been
proposed as an alternative to surgery. Results are encouraging but some problems
remain. We developed a new concept of stent, the Multilayer Stent (MS) to treat
aneurysms and try to avoid some drawbacks encountered with endografts
Methods: This M.S is a 3 Dimensional braided tube made of several interconnected
layers without any covering. Our earliest tests in vitro tests (theorical simulation,
computerized Fluid dynamics, Molecular Modelization) and in vivo tests demonstrate
that this MS reduces the velocity in the aneurismal sac up to 90% by modifying the
hemodynamic conditions. A saccular aneurysm without collateral branch will
thrombose quickly. If a collateral branch is present the flow is directed towards this
branch leading to shrinkage of the aneurysm. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this MS preserves the
collateral branches allowing the possibility to cover any artery without compromising
the flow (renal, digestive arteries, supra aortic vessels…)
Results: 4 PA were treated with the MS (male: 4, mean age: 65 y.) 6 stents (Ø6 to 8
mm, length 40 to 120 mm) were implanted by percutaneous ipsilateral femoral
approach through 8F sheath. Technical success in all patients. All aneurysm
thrombosed. Mid-term follow up will be presented
Conclusion: A new concept of stent, the MS is developed to treat aneurysm. It opens
a new approach to treat peripheral aneurysms avoiding most of the complications
encountered with current endovascular techniques. The results obtained seem
promising. A larger study is ongoing
TCT-568
Ten-Year Outcomes After Revascularization of Peripheral Arterial Disease with
Adjunctive Atherectomy
Alix J. Tercius, Tonga Nfor, M. Fuad Jan, Anjan Gupta, Tanvir Bajwa, Suhail
Allaqaband
Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers,
University of Wisconsin School of Medicine and Public Health, Milwaukee, WI
Background: Atherectomy is sometimes used during revascularization of peripheral
arterial disease (PAD), but its impact on outcomes warrants further investigation.
Methods: We reviewed records of patients with PAD revascularized from January
2000 to December 2007 and follow-up through March 2011. Revascularized patients
who received atherectomy, thrombectomy or endarterectomy were included in the
atherectomy group, which was compared to the routine revascularization group.
Primary end point was a composite of target vessel revascularization (TVR),
amputation or death from any cause.
Results: Of 415 cases (300 patients), 74 cases (53 patients) made up the atherectomy
group. Revascularization was by percutaneous intervention with stents in 318 cases
and surgical bypass in 97 cases. Event-free survival was better in the routine
revascularization group; log rank p=0.03 (Figure). Irrespective of the method of
revascularization, there was a higher incidence of combined TVR, amputation or death
in the atherectomy group, mainly driven by TVR (Table).
Conclusion: Patients treated with atherectomy for severe peripheral arterial disease
experience a higher incidence of combined TVR, amputation or death.
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